Biotech Showcase™ 2017: Catabasis pursues bifunctional mutation-agnostic approach to DMD

January 26, 2017
Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an NF-κB inhibitor—edasalonexent—as a potential Duchenne muscular dystrophy (DMD) treatment. Speaking at the 2017 Biotech Showcase, Dr. Jill Milne, co-founder, president and CEO of Catabasis, describes to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, the company’s ambitions to pursue a pivotal Phase III trial this year.
Previous Video
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets
Biotech Showcase™ 2017: Q BioMed plans to accelerate up to four more assets

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking t...

Next Video
Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals
Biotech Showcase™ 2017: Grünenthal looks beyond pain for transformative deals

Speaking at the 2017 Biotech Showcase™ in San Francisco, Gruenenthal CEO Gabriel Baertschi reveals his ambi...